ClinicalTrials.gg
RecruitingNCT07227532AdmIREPASUpdated Nov 4, 2026

A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System

An interventional study of Pulsed Field Ablation by VARIPULSE Catheter with TRUPULSE Generator in Atrial Fibrillation, sponsored by Biosense Webster, Inc.. Recruiting at 25 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Biosense Webster, Inc. (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 4, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
276
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Atrial Fibrillation by Johnson & Johnson — 7 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Johnson & Johnson.

Planned enrollment
16th of 58
276 · median 149
Started
2025
with 1 other
No phase
34 of 71
6 open now
Primary completion
2030-12
later than 11 of 11 live
Registered
64th of 71
by date

Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, this one is the 16th largest by planned enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2025, is one of 34 with no phase, reaches primary completion later than 11 of the 11 other live ones, and was the 64th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

7 of the 71 studies in Atrial Fibrillation by Johnson & Johnson are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Atrial Fibrillation by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and effectiveness of the FDA approved VARIPULSE catheter system for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF).

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic paroxysmal Atrial Fibrillation (AF) who, in the opinion of the investigator, are candidates for catheter ablation for AF
  • (that is, ineffective, not tolerated, or not desired) or to at least one Class I/III antiarrhythmic drugs (AAD)
  • Willing and capable of providing consent
  • Able and willing to comply with all pre-, post-, and follow-up testing and requirements

Exclusion criteria

Exclusion Criteria:

  • Previously diagnosed with persistent or long-standing persistent AF (more than [>] 7 days in duration)
  • Previous surgical or catheter ablation for AF
  • Significant congenital anomaly or medical problem that in the opinion of the investigator would be a to catheter ablation for AF
  • Current enrollment in an study evaluating another device or drug
  • less than 12 months
  • Any contraindications as defined in the Protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
276 participants (estimated)

Study arms

  • Experimental
    Pulsed Field Ablation by VARIPULSE Catheter with TRUPULSE Generator

    Participants undergoing electrophysiology mapping and pulsed field ablation (PFA) for management of treatment of symptomatic paroxysmal atrial fibrillation (AF) will undergo pulmonary vein (PV) ablation with the VARIPULSE Catheter with a TRUPULSE Generator.

    Device: Pulsed Field Ablation by VARIPULSE Catheter with TRUPULSE Generator

Interventions

  • DevicePulsed Field Ablation by VARIPULSE Catheter with TRUPULSE Generator

    Pulsed field ablation by VARIPULSE catheter with TRUPULSE generator will be used.

06

What researchers measure

Primary outcomes

  1. Occurences of Early Onset Primary Adverse Events (PAEs) Within 7 days of the Index Ablation Procedure

    PAE's will include the following adverse events: atrio-esophageal fistula, phrenic nerve paralysis, cardiac tamponade/perforation, pulmonary vein stenosis (PVS), device or procedure related death, stroke/cerebrovascular accident (CVA), major vascular access complication/bleeding, thromboembolism, myocardial infarction, transient ischemic attack (TIA), pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis.

    Time frame: Within 7 days post index procedure

  2. Freedom From Documented (Symptomatic and Asymptomatic) Atrial Tachyarrhythmias Episodes

    Freedom from documented (symptomatic and asymptomatic) atrial tachyarrhythmias (atrial fibrillation \[AF\], atrial tachycardia \[AT\] or atrial flutter \[AFL\] of unknown origin) episodes will be reported. AFL of unknown origin is defined as all AFL except those Cavotricuspid isthmus CTI dependent AFL as confirmed by 12-Lead electrocardiogram (ECG) and entrainment maneuvers in an evaluation period study.

    Time frame: Day 61-1095 post-index procedure

07

Study locations

25 of 25 sites recruiting
  • Phoenix Cardiovascular Research Group
    Phoenix, Arizona 85018, United States
    Recruiting
  • Tucson Medical Center Pima Heart and Vascular
    Tucson, Arizona 85704, United States
    Recruiting
  • OC Memorial
    Fountain Valley, California 92708, United States
    Recruiting
  • Community Memorial Hospital
    Ventura, California 93003, United States
    Recruiting
  • Aurora Denver Cardiology Associates
    Aurora, Colorado 80012, United States
    Recruiting
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
    Recruiting
  • HCA Florida Mercy Hospital
    Miami, Florida 33133, United States
    Recruiting
  • Orlando Health Heart and Vascular Institute
    Orlando, Florida 32806, United States
    Recruiting
  • Edward Hospital Midwest Cardiovascular Institute
    Naperville, Illinois 60540, United States
    Recruiting
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
    Recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
  • The Kansas City Heart Rhythm Institute
    Overland Park, Kansas 66211, United States
    Recruiting
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
    Recruiting
  • Trinity Health
    Ypsilanti, Michigan 48197, United States
    Recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
  • Capital Health Regional Medical Center
    Trenton, New Jersey 08638, United States
    Recruiting
  • Northwell Health Physician Partners Cardiology
    Lake Success, New York 11042, United States
    Recruiting
  • Albert Einstein College Of Medicine - Montefiore Medical Center
    The Bronx, New York 10467, United States
    Recruiting
  • The Christ Hospital
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Springfield Medical Center
    Springfield, Ohio 45504, United States
    Recruiting
  • Texas Cardiac Arrhythmia Research Foundation
    Austin, Texas 78705, United States
    Recruiting
  • Baylor Scott and White Research Institute
    Fort Worth, Texas 76104, United States
    Recruiting
  • Baylor Scott & White Research Institute at The Heart Hospital Baylor Plano
    Plano, Texas 75093, United States
    Recruiting
  • Winchester Medical Center
    Winchester, Virginia 22601, United States
    Recruiting
  • Mercy Hospital
    Janesville, Wisconsin 53548, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2030, 62 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 62 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2025
First posted
Nov 12, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • University of Iowa Hospitals and Clinics · Iowa City, United States
  • Henry Ford Health System · Detroit, United States
  • Capital Health Regional Medical Center · Trenton, United States
across 2 updates, Sep 30, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    2 sites added
    Show 2 added (2 United States)
    • Henry Ford Health System · Detroit, United States
    • Capital Health Regional Medical Center · Trenton, United States
    + 1 other change: verification date
  2. Sep 30, 2026
    1 site added
    Show site
    • University of Iowa Hospitals and Clinics · Iowa City, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07227532
Responsible party
Sponsor
First posted
Nov 12, 2025
Start date
Oct 21, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Emily Purcell
Contact
EPurcel1@its.jnj.com
+1 949 230 3701
Biosense Webster, Inc. Clinical Trial
study director · Biosense Webster, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion